Core Laboratories Net Worth

Core Laboratories Net Worth Breakdown

  CLB
The net worth of Core Laboratories NV is the difference between its total assets and liabilities. Core Laboratories' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Core Laboratories' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Core Laboratories' net worth can be used as a measure of its financial health and stability which can help investors to decide if Core Laboratories is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Core Laboratories NV stock.

Core Laboratories Net Worth Analysis

Core Laboratories' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Core Laboratories' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Core Laboratories' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Core Laboratories' net worth analysis. One common approach is to calculate Core Laboratories' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Core Laboratories' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Core Laboratories' net worth. This approach calculates the present value of Core Laboratories' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Core Laboratories' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Core Laboratories' net worth. This involves comparing Core Laboratories' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Core Laboratories' net worth relative to its peers.

Enterprise Value

831.72 Million

To determine if Core Laboratories is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Core Laboratories' net worth research are outlined below:
Core Laboratories generated a negative expected return over the last 90 days
Core Laboratories has high historical volatility and very poor performance
Core Laboratories has a strong financial position based on the latest SEC filings
Over 99.0% of the company shares are held by institutions such as insurance companies
On 27th of May 2025 Core Laboratories paid $ 0.01 per share dividend to its current shareholders
Latest headline from thelincolnianonline.com: Q3 EPS Estimate for Core Laboratories Decreased by Analyst

Core Laboratories Quarterly Good Will

99.44 Million

Core Laboratories uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Core Laboratories NV. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Core Laboratories' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
31st of January 2024
Upcoming Quarterly Report
View
24th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
31st of January 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Core Laboratories Target Price Consensus

Core target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Core Laboratories' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
   5  Hold
Most Core analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Core stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Core Laboratories, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Core Laboratories Target Price Projection

Core Laboratories' current and average target prices are 10.95 and 15.80, respectively. The current price of Core Laboratories is the price at which Core Laboratories NV is currently trading. On the other hand, Core Laboratories' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Core Laboratories Market Quote on 29th of May 2025

Low Price10.81Odds
High Price10.95Odds

10.95

Target Price

Analyst Consensus On Core Laboratories Target Price

Low Estimate14.38Odds
High Estimate17.54Odds

15.8

Historical Lowest Forecast  14.38 Target Price  15.8 Highest Forecast  17.54
Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Core Laboratories NV and the information provided on this page.

Know Core Laboratories' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Core Laboratories is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Core Laboratories NV backward and forwards among themselves. Core Laboratories' institutional investor refers to the entity that pools money to purchase Core Laboratories' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Fred Alger Management, Llc2025-03-31
736.9 K
Btim Corp2025-03-31
610.9 K
Morgan Stanley - Brokerage Accounts2025-03-31
589.6 K
Northern Trust Corp2024-12-31
577.8 K
Charles Schwab Investment Management Inc2025-03-31
498 K
Gendell Jeffrey L2025-03-31
457 K
Bank Of New York Mellon Corp2025-03-31
410.4 K
Hotchkis & Wiley Capital Management Llc2025-03-31
400.8 K
Van Eck Associates Corporation2025-03-31
395.1 K
Ariel Investments, Llc2025-03-31
10.3 M
Blackrock Inc2025-03-31
7.5 M
Note, although Core Laboratories' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Core Laboratories' market capitalization trends

The company currently falls under 'Small-Cap' category with a total capitalization of 526.5 M.

Market Cap

694.08 Million

Project Core Laboratories' profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets 0.06  0.06 
Return On Capital Employed 0.12  0.21 
Return On Assets 0.05  0.10 
Return On Equity 0.12  0.12 
The company has Net Profit Margin of 0.05 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.06 %, which entails that for every 100 dollars of revenue, it generated $0.06 of operating income.
When accessing Core Laboratories' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Core Laboratories' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Core Laboratories' profitability and make more informed investment decisions.
Please note, the presentation of Core Laboratories' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Core Laboratories' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Core Laboratories' management manipulating its earnings.

Evaluate Core Laboratories' management efficiency

Core Laboratories has Return on Asset of 0.053 % which means that on every $100 spent on assets, it made $0.053 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1157 %, implying that it generated $0.1157 on every 100 dollars invested. Core Laboratories' management efficiency ratios could be used to measure how well Core Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At present, Core Laboratories' Return On Capital Employed is projected to slightly decrease based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.1, whereas Return On Tangible Assets are forecasted to decline to 0.06. At present, Core Laboratories' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 25.6 M, whereas Total Assets are forecasted to decline to about 553.5 M.
Last ReportedProjected for Next Year
Book Value Per Share 5.50  5.77 
Tangible Book Value Per Share 3.24  3.40 
Enterprise Value Over EBITDA 13.28  12.56 
Price Book Value Ratio 3.22  6.30 
Enterprise Value Multiple 13.28  12.56 
Price Fair Value 3.22  6.30 
Enterprise Value875.5 M831.7 M
The decision-making processes within Core Laboratories are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue
1.2837
Revenue
517.8 M
Quarterly Revenue Growth
(0.05)
Revenue Per Share
11.046
Return On Equity
0.1157
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Core Laboratories insiders, such as employees or executives, is commonly permitted as long as it does not rely on Core Laboratories' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Core Laboratories insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Core Laboratories Corporate Filings

8K
27th of May 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
19th of May 2025
Other Reports
ViewVerify
15th of May 2025
Other Reports
ViewVerify
F4
5th of May 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
Core Laboratories time-series forecasting models is one of many Core Laboratories' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Core Laboratories' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Core Laboratories Earnings Estimation Breakdown

The calculation of Core Laboratories' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Core Laboratories is estimated to be 0.185 with the future projection ranging from a low of 0.17 to a high of 0.2. Please be aware that this consensus of annual earnings estimates for Core Laboratories NV is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.14
0.17
Lowest
Expected EPS
0.185
0.20
Highest

Core Laboratories Earnings Projection Consensus

Suppose the current estimates of Core Laboratories' value are higher than the current market price of the Core Laboratories stock. In this case, investors may conclude that Core Laboratories is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Core Laboratories' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 30th of June 2025Current EPS (TTM)
592.69%
0.14
0.185
0.59

Core Laboratories Earnings History

Earnings estimate consensus by Core Laboratories analysts from Wall Street is used by the market to judge Core Laboratories' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Core Laboratories' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.

Core Laboratories Quarterly Gross Profit

20.4 Million

At present, Core Laboratories' Retained Earnings are projected to decrease significantly based on the last few years of reporting. The current year's Price Earnings Ratio is expected to grow to 37.26, whereas Retained Earnings Total Equity is forecasted to decline to about 73.5 M. As of May 29, 2025, Common Stock Shares Outstanding is expected to decline to about 40.7 M. In addition to that, Net Income Applicable To Common Shares is expected to decline to about 21.3 M.
Hype
Prediction
LowEstimatedHigh
6.3510.6714.99
Details
Intrinsic
Valuation
LowRealHigh
8.8913.2117.53
Details
5 Analysts
Consensus
LowTargetHigh
14.3815.8017.54
Details
Earnings
Estimates (0)
LowProjected EPSHigh
0.170.180.20
Details
Note that many institutional investors and large investment bankers can move markets due to the volume of Core assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Core Laboratories. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Core Laboratories' stock price in the short term.

Core Laboratories Earnings per Share Projection vs Actual

Actual Earning per Share of Core Laboratories refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Core Laboratories NV predict the company's earnings will be in the future. The higher the earnings per share of Core Laboratories, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Core Laboratories Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Core Laboratories, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Core Laboratories should always be considered in relation to other companies to make a more educated investment decision.

Core Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Core Laboratories' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-04-24
2025-03-310.150.14-0.01
2025-01-30
2024-12-310.220.220.0
2024-10-24
2024-09-300.2340.250.016
2024-07-24
2024-06-300.210.220.01
2024-04-24
2024-03-310.160.190.0318 
2024-01-31
2023-12-310.190.190.0
2023-11-01
2023-09-300.220.220.0
2023-07-26
2023-06-300.20.210.01
2023-04-26
2023-03-310.160.190.0318 
2023-02-01
2022-12-310.20.20.0
2022-10-26
2022-09-300.150.180.0320 
2022-07-27
2022-06-300.140.12-0.0214 
2022-04-27
2022-03-310.090.08-0.0111 
2022-02-02
2021-12-310.20.20.0
2021-10-27
2021-09-300.190.18-0.01
2021-07-28
2021-06-300.190.18-0.01
2021-04-21
2021-03-310.130.150.0215 
2021-01-27
2020-12-310.150.180.0320 
2020-10-21
2020-09-300.150.160.01
2020-07-22
2020-06-300.10.140.0440 
2020-04-22
2020-03-310.340.31-0.03
2020-01-29
2019-12-310.370.380.01
2019-10-23
2019-09-300.490.50.01
2019-07-24
2019-06-300.460.460.0
2019-04-24
2019-03-310.430.440.01
2019-01-30
2018-12-310.490.48-0.01
2018-10-24
2018-09-300.630.640.01
2018-07-25
2018-06-300.590.590.0
2018-04-25
2018-03-310.570.570.0
2018-01-31
2017-12-310.580.580.0
2017-10-23
2017-09-300.440.480.04
2017-07-24
2017-06-300.510.520.01
2017-04-19
2017-03-310.390.420.03
2017-01-25
2016-12-310.40.410.01
2016-10-19
2016-09-300.380.380.0
2016-07-20
2016-06-300.350.350.0
2016-04-20
2016-03-310.370.370.0
2016-01-27
2015-12-310.650.650.0
2015-10-21
2015-09-300.830.830.0
2015-07-22
2015-06-300.770.820.05
2015-04-22
2015-03-310.850.860.01
2015-01-28
2014-12-311.541.540.0
2014-10-22
2014-09-301.521.530.01
2014-07-23
2014-06-301.341.350.01
2014-04-23
2014-03-311.451.450.0
2014-01-29
2013-12-311.411.430.02
2013-10-16
2013-09-301.341.360.02
2013-07-17
2013-06-301.321.320.0
2013-04-17
2013-03-311.151.220.07
2013-01-30
2012-12-311.131.170.04
2012-10-17
2012-09-301.111.130.02
2012-07-18
2012-06-301.151.160.01
2012-04-18
2012-03-311.061.060.0
2012-02-01
2011-12-311.081.090.01
2011-10-19
2011-09-300.991.00.01
2011-07-20
2011-06-300.880.90.02
2011-04-19
2011-03-310.750.770.02
2011-02-09
2010-12-310.810.810.0
2010-10-20
2010-09-300.780.790.01
2010-07-21
2010-06-300.720.750.03
2010-04-28
2010-03-310.660.690.03
2010-02-10
2009-12-310.60.630.03
2009-10-22
2009-09-300.560.570.01
2009-07-22
2009-06-300.620.620.0
2009-04-22
2009-03-310.650.660.01
2009-02-11
2008-12-310.820.880.06
2008-10-22
2008-09-300.790.820.03
2008-07-23
2008-06-300.740.760.02
2008-04-23
2008-03-310.680.690.01
2008-02-13
2007-12-310.670.680.01
2007-10-24
2007-09-300.630.650.02
2007-07-25
2007-06-300.580.590.01
2007-04-23
2007-03-310.490.520.03
2007-02-14
2006-12-310.470.490.02
2006-10-25
2006-09-300.390.420.03
2006-07-26
2006-06-300.30.350.0516 
2006-04-26
2006-03-310.250.290.0416 
2006-02-15
2005-12-310.250.280.0312 
2005-10-26
2005-09-300.210.240.0314 
2005-07-27
2005-06-300.170.190.0211 
2005-04-27
2005-03-310.140.160.0214 
2005-02-23
2004-12-310.160.170.01
2004-10-28
2004-09-300.140.140.0
2004-07-28
2004-06-300.120.120.0
2004-04-28
2004-03-310.080.10.0225 
2004-02-25
2003-12-310.120.120.0
2003-10-29
2003-09-300.10.10.0
2003-07-30
2003-06-300.060.080.0233 
2003-05-09
2003-03-310.050.04-0.0120 
2003-02-28
2002-12-310.090.05-0.0444 
2002-10-24
2002-09-300.080.080.0
2002-07-29
2002-06-300.060.060.0
2002-05-07
2002-03-310.060.05-0.0116 
2002-02-21
2001-12-310.10.10.0
2001-10-25
2001-09-300.140.140.0
2001-07-25
2001-06-300.110.130.0218 
2001-04-26
2001-03-310.090.090.0
2001-02-27
2000-12-310.110.110.0
2000-10-30
2000-09-300.090.090.0
2000-07-28
2000-06-300.060.070.0116 
2000-04-28
2000-03-310.060.05-0.0116 
2000-02-10
1999-12-310.120.120.0
1999-10-29
1999-09-300.090.090.0
1999-07-30
1999-06-300.050.050.0
1999-04-30
1999-03-310.010.020.01100 
1999-03-25
1998-12-310.140.09-0.0535 
1998-10-27
1998-09-300.130.140.01
1998-07-30
1998-06-300.10.120.0220 
1998-04-23
1998-03-310.080.090.0112 
1998-02-26
1997-12-310.110.120.01
1997-10-22
1997-09-300.080.10.0225 
1997-08-14
1997-06-300.070.080.0114 
1997-04-25
1997-03-310.050.050.0
1997-02-26
1996-12-310.060.060.0
1996-10-25
1996-09-300.060.060.0

Core Laboratories Corporate Management

Gwendolyn MBASenior RelationsProfile
J DumasVice President Business DevelopmentProfile
Martha CarnesPresiding Non-Executive Lead Independent Member of the Supervisory BoardProfile
Monique EeuwijkNon-Executive Independent Member of the Supervisory BoardProfile
Jacobus SchoutenManaging DirectorProfile
When determining whether Core Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Core Laboratories' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Core Laboratories Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Core Laboratories Nv Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Core Laboratories NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Oil & Gas Equipment & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Core Laboratories. If investors know Core will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Core Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
2.896
Dividend Share
0.04
Earnings Share
0.59
Revenue Per Share
11.046
Quarterly Revenue Growth
(0.05)
The market value of Core Laboratories is measured differently than its book value, which is the value of Core that is recorded on the company's balance sheet. Investors also form their own opinion of Core Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Core Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Core Laboratories' market value can be influenced by many factors that don't directly affect Core Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Core Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Core Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Core Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.